| gap-pubmed-20260411- | How does WYD simultaneously modulate multiple disconnected pathways (Aβ processi | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Which of the 99 WYD compounds are responsible for neuroprotective effects and wh | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines the balance between AETA's inhibition of ionotropic vs enhanceme | open | 0.72 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | How does neuronal activity regulate AETA production from APP cleavage in vivo? | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What is the molecular mechanism by which AETA induces intracellular conformation | open | 0.80 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | What mechanisms link abnormal UBE3A activity to diverse neurodegenerative diseas | resolved | 0.75 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do bi-directional neuron-glia interactions mediated by UBE3A contribute to b | open | 0.77 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the molecular mechanisms underlying UBE3A secretion and its functional | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodevelopment |
| gap-pubmed-20260411- | Why does PLA2G4C polymorphism show no impact on treatment response unlike other | open | 0.73 | 0.00 | 2026-04-11 | 0 | | neuropsychiatry |
| gap-pubmed-20260411- | Why do PLA2 polymorphism effects on antipsychotic response manifest in a gender- | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neuropsychiatry |
| gap-pubmed-20260411- | What molecular mechanisms link PLA2 gene polymorphisms to differential antipsych | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuropsychiatry |
| gap-pubmed-20260411- | Can therapeutic targeting of S-nitrosylation pathways prevent or reverse mutatio | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does aberrant S-nitrosylation achieve functional specificity to mimic distin | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms determine when physiological S-nitrosylation becomes p | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Does the distinct AUD microglial phenotype directly contribute to heavy drinking | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What molecular mechanisms mediate reactive microglial activation of astrocytes i | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do commonly used microglial markers (Iba1, CD68, P2RY12, CSF1R) show no mRNA | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What distinguishes free versus EV-associated Gal3 in promoting pathogenic tau ac | open | 0.84 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does Gal3 regulate extracellular vesicle biogenesis in response to pTau stim | open | 0.86 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding t | partially_addressed | 0.89 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Do the synaptic changes observed in this acute Aβ model reflect the temporal pro | open | 0.72 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do Western blot and immunocytochemical analyses show discordant results for | open | 0.75 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | What molecular mechanisms drive selective vulnerability of glutamatergic vs GABA | open | 0.80 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | What determines the optimal biomarker combination ratios across different cognit | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do clinical variables improve prediction accuracy in preclinical but not pro | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Which other neuropsychiatric diseases involve Th9 cells beyond Alzheimer's disea | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What are the specific mechanisms by which Th9 cells contribute to Alzheimer's di | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What alternative pathways mediate LRRK2's regulation of α-synuclein aggregation | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do LRRK2 mutations cause α-synuclein pathology in humans but show no interac | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines the 17.1% of patients with ambiguous plasma p-tau217 values requ | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does plasma p-tau217 outperform other phosphorylated tau variants for detect | resolved | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How can DAP12 signaling be selectively targeted to preserve benefits while block | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How can DAP12 deletion simultaneously increase tau pathology yet improve cogniti | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does DAP12 deletion show sex-specific effects, protecting only female tauopa | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How can massive parallel sequencing technologies identify novel EOAD genes beyon | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms underlie the missing genetic etiology in 95% of EOAD p | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms link age-dependent Aβ/P-Tau accumulation to reduced au | resolved | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do reduced Drp1 levels simultaneously enhance mitochondrial clearance and in | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines the selective vulnerability of specific AD neurons to Aβ and P-T | resolved | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do natural compounds mechanistically target ferroptosis pathways for breast | open | 0.75 | 0.00 | 2026-04-11 | 0 | | pharmacology |
| gap-pubmed-20260411- | What are the detailed regulatory mechanisms controlling ferroptosis pathways in | open | 0.80 | 0.00 | 2026-04-11 | 0 | | cancer-biology |
| gap-pubmed-20260411- | What are the 'unexpected actions of HCN channels in the brain' referenced but no | open | 0.72 | 0.00 | 2026-04-11 | 0 | | epilepsychannelopathy |
| gap-pubmed-20260411- | How does transcriptional dysregulation of HCN channels mechanistically contribut | open | 0.82 | 0.00 | 2026-04-11 | 0 | | epilepsychannelopathy |
| gap-pubmed-20260411- | What mechanisms drive the differential temporal regulation of HCN1-4 expression | open | 0.80 | 0.00 | 2026-04-11 | 0 | | epilepsychannelopathy |
| gap-pubmed-20260411- | What determines the cytoplasmic vs nuclear localization difference between SYNCR | open | 0.76 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | How does SYNCRIP's RNA-binding activity relate to its synaptotagmin interactions | open | 0.78 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | What is the functional significance of SYNCRIP's selective binding to specific s | open | 0.79 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | What precise pathophysiological mechanisms link interneuron dysfunction to cogni | open | 0.73 | 0.00 | 2026-04-11 | 0 | | neurodevelopmental-disorders |
| gap-pubmed-20260411- | How do specific GABAergic interneuron subtypes contribute to distinct autism phe | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodevelopmental-disorders |
| gap-pubmed-20260411- | What genetic or environmental factors explain syndrome-specific differences in i | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodevelopmental-disorders |